Another Shipment of Six Short-Period Giant Planets from TESS

We present the discovery and characterization of six short-period, transiting giant planets from NASA's Transiting Exoplanet Survey Satellite (TESS) -- TOI-1811 (TIC 376524552), TOI-2025 (TIC 394050135), TOI-2145 (TIC 88992642), TOI-2152 (TIC 395393265), TOI-2154 (TIC 428787891), & TOI-2497 (TIC 97568467). All six planets orbit bright host stars (8.9 <G< 11.8, 7.7 <K< 10.1). Using a combination of time-series photometric and spectroscopic follow-up observations from the TESS Follow-up Observing Program (TFOP) Working Group, we have determined that the planets are Jovian-sized (R$_{P}$ = 1.00-1.45 R$_{J}$), have masses ranging from 0.92 to 5.35 M$_{J}$, and orbit F, G, and K stars (4753 $<$ T$_{eff}$ $<$ 7360 K). We detect a significant orbital eccentricity for the three longest-period systems in our sample: TOI-2025 b (P = 8.872 days, $e$ = $0.220\pm0.053$), TOI-2145 b (P = 10.261 days, $e$ = $0.182^{+0.039}_{-0.049}$), and TOI-2497 b (P = 10.656 days, $e$ = $0.196^{+0.059}_{-0.053}$). TOI-2145 b and TOI-2497 b both orbit subgiant host stars (3.8 $<$ $\log$ g $<$4.0), but these planets show no sign of inflation despite very high levels of irradiation. The lack of inflation may be explained by the high mass of the planets; $5.35^{+0.32}_{-0.35}$ M$_{\rm J}$ (TOI-2145 b) and $5.21\pm0.52$ M$_{\rm J}$ (TOI-2497 b). These six new discoveries contribute to the larger community effort to use {\it TESS} to create a magnitude-complete, self-consistent sample of giant planets with well-determined parameters for future detailed studies.Comment: 20 Pages, 6 Figures, 8 Tables, Accepted by MNRA

Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial.

Importance: Evidence regarding corticosteroid use for severe coronavirus disease 2019 (COVID-19) is limited. Objective: To determine whether hydrocortisone improves outcome for patients with severe COVID-19. Design, Setting, and Participants: An ongoing adaptive platform trial testing multiple interventions within multiple therapeutic domains, for example, antiviral agents, corticosteroids, or immunoglobulin. Between March 9 and June 17, 2020, 614 adult patients with suspected or confirmed COVID-19 were enrolled and randomized within at least 1 domain following admission to an intensive care unit (ICU) for respiratory or cardiovascular organ support at 121 sites in 8 countries. Of these, 403 were randomized to open-label interventions within the corticosteroid domain. The domain was halted after results from another trial were released. Follow-up ended August 12, 2020. Interventions: The corticosteroid domain randomized participants to a fixed 7-day course of intravenous hydrocortisone (50 mg or 100 mg every 6 hours) (n = 143), a shock-dependent course (50 mg every 6 hours when shock was clinically evident) (n = 152), or no hydrocortisone (n = 108). Main Outcomes and Measures: The primary end point was organ support-free days (days alive and free of ICU-based respiratory or cardiovascular support) within 21 days, where patients who died were assigned -1 day. The primary analysis was a bayesian cumulative logistic model that included all patients enrolled with severe COVID-19, adjusting for age, sex, site, region, time, assignment to interventions within other domains, and domain and intervention eligibility. Superiority was defined as the posterior probability of an odds ratio greater than 1 (threshold for trial conclusion of superiority >99%). Results: After excluding 19 participants who withdrew consent, there were 384 patients (mean age, 60 years; 29% female) randomized to the fixed-dose (n = 137), shock-dependent (n = 146), and no (n = 101) hydrocortisone groups; 379 (99%) completed the study and were included in the analysis. The mean age for the 3 groups ranged between 59.5 and 60.4 years; most patients were male (range, 70.6%-71.5%); mean body mass index ranged between 29.7 and 30.9; and patients receiving mechanical ventilation ranged between 50.0% and 63.5%. For the fixed-dose, shock-dependent, and no hydrocortisone groups, respectively, the median organ support-free days were 0 (IQR, -1 to 15), 0 (IQR, -1 to 13), and 0 (-1 to 11) days (composed of 30%, 26%, and 33% mortality rates and 11.5, 9.5, and 6 median organ support-free days among survivors). The median adjusted odds ratio and bayesian probability of superiority were 1.43 (95% credible interval, 0.91-2.27) and 93% for fixed-dose hydrocortisone, respectively, and were 1.22 (95% credible interval, 0.76-1.94) and 80% for shock-dependent hydrocortisone compared with no hydrocortisone. Serious adverse events were reported in 4 (3%), 5 (3%), and 1 (1%) patients in the fixed-dose, shock-dependent, and no hydrocortisone groups, respectively. Conclusions and Relevance: Among patients with severe COVID-19, treatment with a 7-day fixed-dose course of hydrocortisone or shock-dependent dosing of hydrocortisone, compared with no hydrocortisone, resulted in 93% and 80% probabilities of superiority with regard to the odds of improvement in organ support-free days within 21 days. However, the trial was stopped early and no treatment strategy met prespecified criteria for statistical superiority, precluding definitive conclusions. Trial Registration: ClinicalTrials.gov Identifier: NCT02735707

Verification of Gaia Data Release 3 Single-lined Spectroscopic Binary Solutions With Three Transiting Low-mass Secondaries

While secondary mass inferences based on single-lined spectroscopic binary (SB1) solutions are subject to $\sin i$ degeneracies, this degeneracy can be lifted through the observations of eclipses. We combine the subset of Gaia Data Release 3 SB1 solutions consistent with brown dwarf-mass secondaries with the Transiting Exoplanet Survey Satellite (TESS) Object of Interest (TOI) list to identify three candidate transiting brown dwarf systems. Ground-based precision radial velocity follow-up observations confirm that TOI-2533.01 is a transiting brown dwarf with $M={72}_{-3}^{+3}\,{M}_{\mathrm{Jup}}={0.069}_{-0.003}^{+0.003}\,{M}_{\odot }$ orbiting TYC 2010-124-1 and that TOI-5427.01 is a transiting very low-mass star with $M={93}_{-2}^{+2}\,{M}_{\mathrm{Jup}}={0.088}_{-0.002}^{+0.002}\,{M}_{\odot }$ orbiting UCAC4 515-012898. We validate TOI-1712.01 as a very low-mass star with $M={82}_{-7}^{+7}\,{M}_{\mathrm{Jup}}={0.079}_{-0.007}^{+0.007}\,{M}_{\odot }$ transiting the primary in the hierarchical triple system BD+45 1593. Even after accounting for third light, TOI-1712.01 has a radius nearly a factor of 2 larger than predicted for isolated stars with similar properties. We propose that the intense instellation experienced by TOI-1712.01 diminishes the temperature gradient near its surface, suppresses convection, and leads to its inflated radius. Our analyses verify Gaia DR3 SB1 solutions in the low Doppler semiamplitude limit, thereby providing the foundation for future joint analyses of Gaia radial velocities and Kepler, K2, TESS, and PLAnetary Transits and Oscillations light curves for the characterization of transiting massive brown dwarfs and very low-mass stars

Giant Outer Transiting Exoplanet Mass (GOT ‘EM) Survey. IV. Long-term Doppler Spectroscopy for 11 Stars Thought to Host Cool Giant Exoplanets

Discovering and characterizing exoplanets at the outer edge of the transit method’s sensitivity has proven challenging owing to geometric biases and the practical difficulties associated with acquiring long observational baselines. Nonetheless, a sample of giant exoplanets on orbits longer than 100 days has been identified by transit hunting missions. We present long-term Doppler spectroscopy for 11 such systems with observation baselines spanning a few years to a decade. We model these radial velocity observations jointly with transit photometry to provide initial characterizations of these objects and the systems in which they exist. Specifically, we make new precise mass measurements for four long-period giant exoplanets (Kepler-111 c, Kepler-553 c, Kepler-849 b, and PH-2 b), we place new upper limits on mass for four others (Kepler-421 b, KOI-1431.01, Kepler-1513 b, and Kepler-952 b), and we show that several confirmed planets are in fact not planetary at all. We present these findings to complement similar efforts focused on closer-in short-period giant planets, and with the hope of inspiring future dedicated studies of cool giant exoplanets

HIP 33609 b: An Eccentric Brown Dwarf Transiting a V = 7.3 Rapidly Rotating B Star

We present the discovery and characterization of HIP 33609 b, a transiting warm brown dwarf orbiting a late B star, discovered by NASA's Transiting Exoplanet Survey Satellite as TOI-588 b. HIP 33609 b is a large ( R _b = ${1.580}_{-0.070}^{+0.074}$ R _J ) brown dwarf on a highly eccentric ( e = ${0.560}_{-0.031}^{+0.029}$ ) orbit with a 39 days period. The host star is a bright ( V = 7.3 mag), T _eff = 10,400 ${}_{-660}^{+800}$ K star with a mass of M _* = ${2.383}_{-0.095}^{+0.10}$ M _⊙ and radius of R _* = ${1.863}_{-0.082}^{+0.087}$ R _⊙ , making it the hottest transiting brown dwarf host star discovered to date. We obtained radial velocity measurements from the CHIRON spectrograph confirming the companion's mass of M _b = ${68.0}_{-7.1}^{+7.4}$ M _J as well as the host star's rotation rate ( $v\sin {i}_{* }=55.6\pm 1.8$ km s ^−1 ). We also present the discovery of a new comoving group of stars, designated as MELANGE-6, and determine that HIP 33609 is a member. We use a combination of rotation periods and isochrone models fit to the cluster members to estimate an age of 150 ± 25 Myr. With a measured mass, radius, and age, HIP 33609 b becomes a benchmark for substellar evolutionary models